Merck, 700053P-1MG, 25-hydroxycholesterol-d6

General description
25-hydroxycholesterol (25HC) is synthesized from cholesterol in the presence of oxygen and enzyme cholesterol 25-hydroxylase and the conversion is dependent on nicotinamide adenine dinucleotide phosphate (NADPH) during toll-like receptor activation. 25HC is catabolized to 7α-hydroxylated sterol. 25-hydroxycholesterol-d6 is the deuterated form of 25-hydroxycholesterol.
Application
25-hydroxycholesterol-d6 has been used as an internal standard:
in the quantification of 25-OHC in jejunum samples by liquid chromatography with tandem mass spectrometry (LC-MS-MS)
in plasma samples by liquid chromatography-mass spectrometry analysis
for calibration curve generation for plasma oxysterol quantification

Biochem/physiol Actions
25-hydroxycholesterol is a liver X receptor ligand. This bioactive lipid regulates immune response and macrophages production from monocytes. 25-HC serves as an antiviral effector and may have therapeutic potential. It reduces cholesterol biosynthesis by inactivating sterol regulatory element binding protein and inhibits HMG-CoA reductase (HMGCR). 25-HC may play a protective role in myocardial ischemia-reperfusion injury by inhibiting apoptosis and regulating mitogen-activated protein kinase (MAPK) pathway.
Packaging
5 mL Amber Glass Screw Cap Vial (700053P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC